Repeated superselective intraarterial bevacizumab after blood brain barrier disruption for newly diagnosed glioblastoma: a phase I/II clinical trial.
Bevacizumab
Blood brain barrier
Chemotherapy
Glioblastoma
High-grade glioma
Intra-arterial infusion
Journal
Journal of neuro-oncology
ISSN: 1573-7373
Titre abrégé: J Neurooncol
Pays: United States
ID NLM: 8309335
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
09
08
2021
accepted:
18
09
2021
pubmed:
4
10
2021
medline:
8
3
2022
entrez:
3
10
2021
Statut:
ppublish
Résumé
Pre-clinical evidence suggests bevacizumab (BV) depletes the GBM peri-vascular cancer-stem cell niche. This phase I/II study assesses the safety and efficacy of repeated doses of superselective intra-arterial cerebral infusion (SIACI) of BV after blood-brain barrier disruption (BBBD). Date of surgery was day 0. Evaluated patients received repeated SIACI bevacizumab (15 mg/kg) with BBBD at days 30 ± 7, 120 ± 7, and 210 ± 7 along with 6 weeks of standard chemoradiation. Response assessment in neuro-oncology criteria and the Kaplan-Meier product-limit method was used to evaluate progression free and overall survival (PFS and OS, respectively). Twenty-three patients with a median age of 60.5 years (SD = 12.6; 24.7-78.3) were included. Isocitrate dehydrogenase mutation was found in 1/23 (4%) patients. MGMT status was available for 11/23 patients (7 unmethylated; 3 methylated; 1 inconclusive). Median tumor volume was 24.0 cm3 (SD = 31.1, 1.7-48.3 cm Repeated dosing of IA BV after BBBD offers an encouraging outcome in terms of PFS and OS. Phase III trials are warranted to determine whether repeated IA BV combined with Stupp protocol is superior to Stupp protocol alone for newly diagnosed GBM.
Identifiants
pubmed: 34601657
doi: 10.1007/s11060-021-03851-2
pii: 10.1007/s11060-021-03851-2
doi:
Substances chimiques
Bevacizumab
2S9ZZM9Q9V
Types de publication
Clinical Trial, Phase I
Clinical Trial, Phase II
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
117-124Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Burkhardt JK, Riina HA, Shin BJ, Moliterno JA, Hofstetter CP, Boockvar JA (2011) Intra-arterial chemotherapy for malignant gliomas: a critical analysis. Interv Neuroradiol 17(3):286–295
doi: 10.1177/159101991101700302
Carson KA, Grossman SA, Fisher JD, Shaw EG (2007) Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials. J Clin Oncol 25(18):2601–2606
doi: 10.1200/JCO.2006.08.1661
Boockvar JA, Tsiouris AJ, Hofstetter CP et al (2011) Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma. J Neurosurg 114(3):624–632
doi: 10.3171/2010.9.JNS101223
Theodotou C, Shah AH, Hayes S et al (2014) The role of intra-arterial chemotherapy as an adjuvant treatment for glioblastoma. Br J Neurosurg 28(4):438–446
doi: 10.3109/02688697.2013.877122
Lesniak WG, Chu C, Jablonska A et al (2019) A distinct advantage to intraarterial delivery of (89)Zr-Bevacizumab in PET imaging of mice with and without osmotic opening of the blood-brain barrier. J Nucl Med 60(5):617–622
doi: 10.2967/jnumed.118.218792
Burkhardt JK, Riina H, Shin BJ et al (2012) Intra-arterial delivery of bevacizumab after blood-brain barrier disruption for the treatment of recurrent glioblastoma: progression-free survival and overall survival. World Neurosurg 77(1):130–134
doi: 10.1016/j.wneu.2011.05.056
Wang R, Chadalavada K, Wilshire J et al (2010) Glioblastoma stem-like cells give rise to tumour endothelium. Nature 468(7325):829–833
doi: 10.1038/nature09624
Gilbert MR, Dignam JJ, Armstrong TS et al (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370(8):699–708
doi: 10.1056/NEJMoa1308573
Schemper M, Smith TL (1996) A note on quantifying follow-up in studies of failure time. Control Clin Trials 17(4):343–346
doi: 10.1016/0197-2456(96)00075-X
Chinot OL, Wick W, Mason W et al (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370(8):709–722
doi: 10.1056/NEJMoa1308345
Gilbert MR, Wang M, Aldape KD et al (2013) Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol 31(32):4085–4091
doi: 10.1200/JCO.2013.49.6968
Abrams M, Reichman N, Khatri D et al (2020) Update on glioma biotechnology. Clin Neurol Neurosurg 195:106075
doi: 10.1016/j.clineuro.2020.106075
Stupp R, Hegi ME, Gorlia T et al (2014) Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071–22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 15(10):1100–1108
doi: 10.1016/S1470-2045(14)70379-1
Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996
doi: 10.1056/NEJMoa043330
Stupp R, Taillibert S, Kanner A et al (2017) Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA 318(23):2306–2316
doi: 10.1001/jama.2017.18718
McCrea HJ, Ivanidze J, O’Connor A et al (2021) Intraarterial delivery of bevacizumab and cetuximab utilizing blood-brain barrier disruption in children with high-grade glioma and diffuse intrinsic pontine glioma: results of a phase I trial. J Neurosurg Pediatr. https://doi.org/10.3171/2021.3.PEDS20738
doi: 10.3171/2021.3.PEDS20738
pubmed: 34359048
Patel NV, Khatri D, D’Amico R et al (2020) Vascularized temporoparietal fascial flap: a novel surgical technique to bypass the blood-brain barrier in glioblastoma. World Neurosurg 143:38–45
doi: 10.1016/j.wneu.2020.07.132
Neuwelt EA, Frenkel EP, Diehl J, Vu LH, Rapoport S, Hill S (1980) Reversible osmotic blood-brain barrier disruption in humans: implications for the chemotherapy of malignant brain tumors. Neurosurgery 7(1):44–52
doi: 10.1227/00006123-198007000-00007
D’Amico RS, Khatri D, Reichman N et al (2020) Super selective intra-arterial cerebral infusion of modern chemotherapeutics after blood-brain barrier disruption: where are we now, and where we are going. J Neurooncol 147(2):261–278
doi: 10.1007/s11060-020-03435-6
Schuster JM, Friedman HS, Archer GE et al (1993) Intraarterial therapy of human glioma xenografts in athymic rats using 4-hydroperoxycyclophosphamide. Cancer Res 53(10 Suppl):2338–2343
pubmed: 8485721
Kim MM, Umemura Y, Leung D (2018) Bevacizumab and glioblastoma: past, present, and future directions. Cancer J 24(4):180–186
doi: 10.1097/PPO.0000000000000326
Jo JT, Schiff D, Perry JR (2014) Thrombosis in brain tumors. Semin Thromb Hemost 40(3):325–331
doi: 10.1055/s-0034-1370791
Li X, Huang R, Xu Z (2015) Risk of adverse vascular events in newly diagnosed glioblastoma multiforme patients treated with bevacizumab: a systematic review and meta-analysis. Sci Rep 5:14698
doi: 10.1038/srep14698
Reardon DA, Brandes AA, Omuro A et al (2020) Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the checkmate 143 phase 3 randomized clinical trial. JAMA Oncol 6(7):1003–1010
doi: 10.1001/jamaoncol.2020.1024
Liau LM, Ashkan K, Tran DD et al (2018) First results on survival from a large phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J Transl Med 16(1):142
doi: 10.1186/s12967-018-1507-6
Bao S, Wu Q, Sathornsumetee S et al (2006) Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 66(16):7843–7848
doi: 10.1158/0008-5472.CAN-06-1010
Lucio-Eterovic AK, Piao Y, de Groot JF (2009) Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Clin Cancer Res 15(14):4589–4599
doi: 10.1158/1078-0432.CCR-09-0575
Singh A, Yadav CB, Tabassum N, Bajpeyee AK, Verma V (2019) Stem cell niche: dynamic neighbor of stem cells. Eur J Cell Biol 98(2–4):65–73
doi: 10.1016/j.ejcb.2018.12.001
von Baumgarten L, Brucker D, Tirniceru A et al (2011) Bevacizumab has differential and dose-dependent effects on glioma blood vessels and tumor cells. Clin Cancer Res 17(19):6192–6205
doi: 10.1158/1078-0432.CCR-10-1868
Calabrese C, Poppleton H, Kocak M et al (2007) A perivascular niche for brain tumor stem cells. Cancer Cell 11(1):69–82
doi: 10.1016/j.ccr.2006.11.020
Wang X, Prager BC, Wu Q et al (2018) Reciprocal signaling between glioblastoma stem cells and differentiated tumor cells promotes malignant progression. Cell Stem Cell 22(4):514-528.e515
doi: 10.1016/j.stem.2018.03.011
Schmidt B, Lee HJ, Ryeom S, Yoon SS (2012) Combining bevacizumab with radiation or chemoradiation for solid tumors: a review of the scientific rationale, and clinical trials. Curr Angiogenes 1(3):169–179
doi: 10.2174/2211552811201030169
Louis DN, Perry A, Wesseling P et al (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23(8):1231–1251
doi: 10.1093/neuonc/noab106